Navigation Links
Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device
Date:3/8/2011

MOUNTAIN VIEW, Calif., March 9, 2011 /PRNewswire/ -- AccessClosure, Inc., the U.S. market segment leader in extravascular closure devices, announced today results from the first published study* (Journal of NeuroInterventional Surgery) comparing the pain associated with deployment of different vascular closure devices (VCD) as the primary endpoint.  The single-blinded, randomized, single-center, controlled trial compared the discomfort associated with the Mynx 5F Vascular Closure Device versus the Angio-Seal Evolution Device.  Both pain at closure and the pain increase from baseline to closure were significantly higher in patients undergoing closure with the Angio-Seal Evolution device (p=0.009 and 0.002, respectively).  There was no difference in the rate of closure success or closure complications between the devices.

"This is an important study for physicians and patients,'' said Gregory D. Casciaro, President and CEO of AccessClosure.  "The study scientifically examined whether the Mynx device reduced the pain associated with arteriotomy closure seen with the Angio-Seal Evolution device and provides an evidence-based understanding that will help guide choice about VCD options."

The Institutional Review Board-approved study provided for enrollment of 128 patients based on power analyses with the intention of performing preliminary statistical analysis following enrollment of 64 patients (32 patients in each arm).  Patients, nurses administering a commonly utilized, well-validated visual analog scale (VAS) to assess patient pain, and study coordinators were blinded to the VCD treatment.  The primary end point was defined as the change in pain from baseline (pre-closure) to post-closure, assessed by the VAS.  The patient's reporting of the most painful part of the procedure from a multiple choice selection (1. Lidocaine injection and access, 2. contrast injection and 3. closure) was a secondary endpoint along with
'/>"/>

SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Georgia Health Sciences University Clinical Study Shows RyMed InVision-PlusĀ® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
2. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
3. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
4. Structured Diabetes Management can Significantly Improve Overall Glycemic Control and Reduce HbA1c Values in Non-insulin Treated Type 2 Diabetes
5. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
6. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
7. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
8. STALLERGENES : Significant Growth : Q3 2010 + 10% and +12% Over the First 9 Months / Shionogi Partnership: First EUR24 Million Instalment
9. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
10. Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
11. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a company overview at the ... a.m. ET in Boston, MA. ... on the "Investors & Media" section of the Company,s website, ... Isis website within 48 hours and will be archived for ...
(Date:10/30/2014)... 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... conference call and live audio webcast on Thursday, November ... third quarter 2014 financial results. Interested participants ... (888) 347-1165 for domestic callers or (412) 902-4276 for ... under the investor relations section of the Regado website ...
(Date:10/30/2014)... DENVER (Oct. 29, 2014) – The severe flooding that ... have been less destructive if the bridges, roads and ... a new study from the University of Colorado Denver. ... of infrastructure," said Jimmy Kim, PhD, associate professor of ... and Applied Science and lead author the study. "There ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... HILL, N.C., Jan. 12, 2011 Cempra Pharmaceuticals ... of solithromycin (CEM-101), the first fluoroketolide antibiotic, at ... Advanced Research and Development Authority (BARDA) industry day ...   Solithromycin is a clinical-stage fluoroketolide ...
... Jan. 11, 2011 Fred Hutchinson Cancer Research Center ... Robert Eisenman, Ph.D., a molecular biologist and geneticist, have ... Advancement of Science, or AAAS. Election as a fellow ... peers. Brent, a member of the Hutchinson ...
... 2011 Regenicin, Inc. (OTC Bulletin Board: ... of regenerative cell therapies to restore the health of ... annual OneMedForum at the Sir Francis Drake Hotel in ... McCoy, will present Regenicin,s core business model and strategic ...
Cached Biology Technology:Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 2Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 3Roger Brent and Robert Eisenman Named AAAS Fellows 2Roger Brent and Robert Eisenman Named AAAS Fellows 3Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen records ... into a human-readable text developed in manuscript within the ... to study the species distributions of ten Nearctic species ... is originally designed to support the generation and application ...
(Date:10/29/2014)... organisms in the living world compete with members ... in how much they invest into their competitive ... to get access to high-quality resources, while others ... of the lower-quality resources that are left over ... animal and human societies seems to fluctuate considerably ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... Many plants produce toxic chemicals to protect themselves ... flower structures that prevent pollinators such as bees from ... evidence that flowering plants might also use chemical defences ... are published next week in the British Ecological Society,s ...
... MA - It is estimated that up to 10 ... of renal disease, with 450,000 patients with end stage ... Women,s Hospital, Massachusetts General Hospital and the University of ... be transplanted from one fish to another to regenerate ...
... students to ultimately provide quality patient care medical schools should ... the core disciplines of medicine, according to a study in ... College of Radiology ( www.jacr.org ). Physiology is the ... is vital that medical schools provide first-rate physiology education for ...
Cached Biology News:Secret life of bees now a little less secret 2Researchers unlock the potential for exploring kidney regeneration 2